Birzeit Pharmaceutical Co (XPAE:BPC) Total Stockholders Equity: $117.02 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XPAE:BPC Birzeit Pharmaceutical Co XPAE:BPC
83 GF Score
Price $3.61
GF Value $4.33
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Birzeit Pharmaceutical Co Total Stockholders Equity?

Birzeit Pharmaceutical Co XPAE:BPC 83 Total Stockholders Equity is $117.02 Mil as of Jun. 2026. GuruFocus rates XPAE:BPC with a GF Score™ of 83/100 and a GF Value™ of $4.33 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Birzeit Pharmaceutical Co's Total Stockholders Equity for the quarter that ended in Jun. 2026 was $117.02 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Birzeit Pharmaceutical Co's Book Value per Share for the quarter that ended in Jun. 2026 was $3.02. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Birzeit Pharmaceutical Co's Debt-to-Equity for the quarter that ended in Jun. 2026 was 0.01.

Birzeit Pharmaceutical Co  (XPAE:BPC) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Birzeit Pharmaceutical Co's Book Value per Share for the quarter that ended in Jun. 2026 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(117.017-0)/38.765
=3.02

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Birzeit Pharmaceutical Co's Debt-to-Equity for the quarter that ended in Jun. 2026 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.664 + 0) / 117.017
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Birzeit Pharmaceutical Co Total Stockholders Equity Related Terms

Birzeit Pharmaceutical Co Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Birzeit Pharmaceutical Co's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Birzeit Pharmaceutical Co Total Stockholders Equity Chart

Birzeit Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 91.87 102.59 104.32 104.20 114.63

Birzeit Pharmaceutical Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 108.18 109.23 114.63 114.38 117.02
XPAE:BPC
83GF Score
Birzeit Pharmaceutical Co XPAE:BPC
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of $117.02 Mil mean?
Birzeit Pharmaceutical Co (XPAE:BPC) has a Total Stockholders Equity of $117.02 Mil as of Jun. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Birzeit Pharmaceutical Co and its competitors.
Is Birzeit Pharmaceutical Co's Total Stockholders Equity too high?
Birzeit Pharmaceutical Co's current Total Stockholders Equity is $117.02 Mil. Overall, Birzeit Pharmaceutical Co has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Birzeit Pharmaceutical Co's Total Stockholders Equity compare to ZTS and UTHR?
Birzeit Pharmaceutical Co's Total Stockholders Equity of $117.02 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Drug Manufacturers company?
A good Total Stockholders Equity depends on the Drug Manufacturers industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Birzeit Pharmaceutical Co and its competitors. Birzeit Pharmaceutical Co's current Total Stockholders Equity is $117.02 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Birzeit Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Birzeit Pharmaceutical Co (XPAE:BPC) is currently considered Modestly Undervalued. The stock's GF Value™ is $4.33, compared to a current price of $3.61 — trading 16.6% below its estimated fair value. The current Total Stockholders Equity is $117.02 Mil. Birzeit Pharmaceutical Co's overall GF Score™ is 83/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Birzeit Pharmaceutical Co (XPAE:BPC), the current Total Stockholders Equity is $117.02 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Birzeit Pharmaceutical Co (XPAE:BPC) Overvalued in 2026?

Based on GuruFocus' analysis, Birzeit Pharmaceutical Co stock appears to be undervalued. The current stock price of $3.61 is trading 16.6% below its estimated GF Value™ of $4.33. GuruFocus considers Birzeit Pharmaceutical Co to be Modestly Undervalued.

Key valuation signals for XPAE:BPC:

  • Total Stockholders Equity: $117.02 Mil
  • GF Value™: $4.33 vs. price of $3.61 (16.6% below fair value)
  • GF Score™: 83/100 with 5 warning signs

No single metric tells the full story. See the XPAE:BPC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Birzeit Pharmaceutical Co Business Description

Address 20 Shatella Street, Betunia Industrial Area, Ramallah, PSE
Birzeit Pharmaceutical Co operates as a pharmaceutical manufacturer in Palestine, producing a range of approximately 270 products across various production lines at four locations. Its portfolio comprises brands spanning multiple therapeutic areas. In addition to manufacturing, the company supplies its products to the local market through pharmacies and medical professionals.
83GF Score

Get the complete analysis for XPAE:BPC

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.61
Price
$4.33
GF Value